{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:15:05Z","timestamp":1794550505198,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A potent graft-versus-leukemia (GVL) response is crucial in preventing relapse, the major impediment to successful allogeneic hematopoietic cell transplantation (HCT). In preclinical studies, type 1 interferon (IFN-\u03b1) enhanced cross-presentation of leukemia-specific antigens by CD8\u03b1 dendritic cells (DCs) and amplified GVL. This observation was translated into a proof-of-concept phase 1\/2 clinical trial with long-acting IFN-\u03b1 (pegylated IFN-\u03b1 [pegIFN\u03b1]) in patients undergoing HCT for high-risk acute myeloid leukemia (AML). Patients with treatment-resistant AML not in remission or those with poor-risk leukemia were administered 4 dosages of pegIFN\u03b1 every 14 days beginning at day \u22121 before HCT. Dose selection was established by adaptive design that continuously assessed the probability of dose-limiting toxicities throughout the trial. Efficacy was evaluated by determining the 6-month incidence of relapse at the maximum tolerated dose (MTD). Thirty-six patients (median age, 60 years) received pegIFN\u03b1 treatment. Grade 3 or greater severe adverse events occurred in 25% of patients, establishing 180 \u03bcg as the MTD. In phase 2, the incidence of relapse was 39% at 6 months, which was sustained through 1-year post-HCT. The incidence of transplant-related mortality was 13%, and severe grade III-IV acute graft-versus-host disease (GVHD) occurred in 11%. Paired blood samples from donors and recipients after HCT revealed elevated levels of type 1 IFN with cellular response, the persistence of cross-presenting DCs, and circulating leukemia antigen-specific T cells. These data suggest that prophylactic administration of pegIFN\u03b1 is feasible in the peri-HCT period. In high-risk AML, increased toxicity was not observed with preliminary evidence for reduction in leukemia relapse after HCT. This trial was registered at www.clinicaltrials.gov as #NCT02328755.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004908","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:55:44Z","timestamp":1633395344000},"page":"5047-5056","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Type 1 interferon to prevent leukemia relapse after allogeneic transplantation"],"prefix":"10.1182","volume":"5","author":[{"given":"John M.","family":"Magenau","sequence":"first","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-9894","authenticated-orcid":false,"given":"Dan","family":"Peltier","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Riwes","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaphol","family":"Pawarode","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Parkin","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anand","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Yanik","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-3834","authenticated-orcid":false,"given":"Sung Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Reddy","sequence":"additional","affiliation":[{"name":"Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2021120316280862800_B1","author":"Pasquini"},{"issue":"23","key":"2021120316280862800_B2","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer."},{"issue":"3","key":"2021120316280862800_B3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"31","key":"2021120316280862800_B4","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021120316280862800_B5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021120316280862800_B6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/nm1309","article-title":"A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses","volume":"11","author":"Reddy","year":"2005","journal-title":"Nat Med."},{"issue":"5426","key":"2021120316280862800_B7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science."},{"issue":"8","key":"2021120316280862800_B8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"2021120316280862800_B9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J Exp Med."},{"issue":"10","key":"2021120316280862800_B10","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med."},{"issue":"20","key":"2021120316280862800_B11","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2012-05-432872","article-title":"Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation","volume":"121","author":"Toubai","year":"2013","journal-title":"Blood."},{"issue":"7","key":"2021120316280862800_B12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J Exp Med."},{"issue":"12","key":"2021120316280862800_B13","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2010-12-325746","article-title":"Type I-IFNs control GVHD and GVL responses after transplantation","volume":"118","author":"Robb","year":"2011","journal-title":"Blood."},{"issue":"7028","key":"2021120316280862800_B14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nature03326","article-title":"Toll-like receptor 3 promotes cross-priming to virus-infected cells","volume":"433","author":"Schulz","year":"2005","journal-title":"Nature."},{"issue":"4","key":"2021120316280862800_B15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Huber","year":"2011","journal-title":"Immunology."},{"issue":"1","key":"2021120316280862800_B16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2009.08029.x","article-title":"Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis","volume":"149","author":"Berneman","year":"2010","journal-title":"Br J Haematol."},{"key":"2021120316280862800_B17","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1590-8658(07)80021-1","article-title":"HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig Liver Dis."},{"issue":"32","key":"2021120316280862800_B18","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021120316280862800_B19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2021120316280862800_B20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bmt.2016.188","article-title":"A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Magenau","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"2021120316280862800_B21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021120316280862800_B22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2141.2009.07770.x","article-title":"High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival","volume":"146","author":"Jacobsohn","year":"2009","journal-title":"Br J Haematol."},{"issue":"7","key":"2021120316280862800_B23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/bmt.2016.325","article-title":"Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"52","author":"Todisco","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2021120316280862800_B24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2011-07-367508","article-title":"Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies","volume":"119","author":"Kayser","year":"2012","journal-title":"Blood."},{"issue":"2","key":"2021120316280862800_B25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","article-title":"Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"18","author":"Armand","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021120316280862800_B26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bmt.2015.170","article-title":"FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML","volume":"51","author":"Song","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"14","key":"2021120316280862800_B27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","article-title":"Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials","volume":"31","author":"Ji","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021120316280862800_B28","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"446","key":"2021120316280862800_B29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc."},{"issue":"24","key":"2021120316280862800_B30","doi-asserted-by":"crossref","first-page":"16693","DOI":"10.1074\/jbc.M709923200","article-title":"CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes","volume":"283","author":"Huysamen","year":"2008","journal-title":"J Biol Chem."},{"issue":"1","key":"2021120316280862800_B31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood."},{"issue":"23","key":"2021120316280862800_B32","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021120316280862800_B33","first-page":"115","article-title":"Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation","volume":"1","author":"Giralt","year":"1995","journal-title":"Cytokines Mol Ther."},{"issue":"2","key":"2021120316280862800_B34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1700859","article-title":"Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients","volume":"20","author":"Mehta","year":"1997","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2021120316280862800_B35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-\u03b1 in acute myeloid leukemia: an old drug revisited","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia."},{"issue":"11","key":"2021120316280862800_B36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2021120316280862800_B37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021120316280862800_B38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood."},{"issue":"23","key":"2021120316280862800_B39","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2021120316280862800_B40","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/s41467-020-17991-y","article-title":"T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5047\/1848868\/advancesadv2021004908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5047\/1848868\/advancesadv2021004908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T16:29:13Z","timestamp":1638548953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5047\/477151\/Type-1-interferon-to-prevent-leukemia-relapse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004908","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}